{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T22:09:18Z","timestamp":1769551758694,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100007509","name":"SEPAR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007509","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archivos de Bronconeumolog\u00eda"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.arbres.2023.07.015","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T19:20:49Z","timestamp":1690053649000},"page":"725-735","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Inhaled Maintenance Therapy in the Follow-Up of COPD in Outpatient Respiratory Clinics. Factors Related to Inhaled Corticosteroid Use. EPOCONSUL 2021 Audit"],"prefix":"10.1016","volume":"59","author":[{"given":"Myriam","family":"Calle Rubio","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Miravitlles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Luis","family":"L\u00f3pez-Campos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernardino","family":"Alc\u00e1zar Navarrete","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Jos\u00e9","family":"Soler Catalu\u00f1a","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel E.","family":"Fuentes Ferrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Luis","family":"Rodr\u00edguez Hermosa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.arbres.2023.07.015_bib0195","unstructured":"Global strategy for prevention, diagnosis and management of COPD: 2023 report. Available from: https:\/\/goldcopd.org\/2023-gold-report-2 [accessed 2.5.23]."},{"key":"10.1016\/j.arbres.2023.07.015_bib0200","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.arbres.2021.03.005","article-title":"Spanish COPD Guidelines (GesEPOC) 2021: updated pharmacological treatment of stable COPD","volume":"58","author":"Miravitlles","year":"2022","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2023.07.015_bib0205","unstructured":"NICE guideline \u2013 chronic obstructive pulmonary disease in over 16s: diagnosis and management; 2019. Available from: https:\/\/www.nice.org.uk\/guidance\/ng115 [accessed 2.5.23]."},{"key":"10.1016\/j.arbres.2023.07.015_bib0210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.arbres.2020.08.002","article-title":"GesEPOC 2021: one more step towards personalized treatment of COPD","volume":"57","author":"Miravitlles","year":"2021","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2023.07.015_bib0215","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.arbr.2017.11.019","article-title":"Medical care according to risk level and adaptation to Spanish COPD guidelines (Gesepoc): the EPOCONSUL study","volume":"54","author":"Calle","year":"2018","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2023.07.015_bib0220","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.arbres.2018.12.002","article-title":"Prognostic validation using GesEPOC 2017 severity criteria","volume":"55","author":"Cabrera L\u00f3pez","year":"2019","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2023.07.015_bib0225","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.arbres.2018.01.035","article-title":"Risk stratification in chronic obstructive pulmonary disease. Can the Spanish guidelines be improved?","volume":"54","author":"Golpe","year":"2018","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2023.07.015_bib0230","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa1713901","article-title":"Once-daily single-inhaler triple versus dual therapy in patients with COPD","volume":"378","author":"Lipson","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arbres.2023.07.015_bib0235","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1916046","article-title":"Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD","volume":"383","author":"Rabe","year":"2020","journal-title":"N Engl J Med"},{"issue":"10048","key":"10.1016\/j.arbres.2023.07.015_bib0240","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/S0140-6736(16)31354-X","article-title":"Single inhaler triple therapy versus inhaled corticosteroid plus long-acting \u03b22-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial","volume":"388","author":"Singh","year":"2016","journal-title":"Lancet"},{"issue":"10125","key":"10.1016\/j.arbres.2023.07.015_bib0245","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S0140-6736(18)30206-X","article-title":"Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial","volume":"391","author":"Papi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.arbres.2023.07.015_bib0250","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.arbres.2019.12.015","article-title":"Blood eosinophil counts and their variability and risk of exacerbations in COPD: a population-based study","volume":"57","author":"Miravitlles","year":"2021","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2023.07.015_bib0255","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1164\/rccm.201912-2384PP","article-title":"Blood eosinophil counts in clinical trials for chronic obstructive pulmonary disease","volume":"202","author":"Singh","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.arbres.2023.07.015_bib0260","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2147\/COPD.S122013","article-title":"Initiation of triple therapy maintenance treatment among patients with COPD in the US","volume":"12","author":"Simeone","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2023.07.015_bib0265","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2147\/COPD.S129007","article-title":"A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy","volume":"12","author":"Mapel","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2023.07.015_bib0270","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41533-017-0040-z","article-title":"Determinants of initial inhaled corticosteroid use in patients with GOLD A\/B COPD: a retrospective study of UK general practice","volume":"27","author":"Chalmers","year":"2017","journal-title":"NPJ Prim Care Respir Med"},{"key":"10.1016\/j.arbres.2023.07.015_bib0275","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2147\/COPD.S124482","article-title":"Clinical audit of COPD in outpatient respiratory clinics in Spain: the EPOCONSUL study","volume":"12","author":"Calle Rubio","year":"2017","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2023.07.015_bib0280","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.arbres.2023.02.004","article-title":"Variations in chronic obstructive pulmonary disease outpatient care in respiratory clinics: results from the 2021 EPOCONSUL audit","volume":"59","author":"Calle Rubio","year":"2023","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2023.07.015_bib0285","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.arbres.2020.06.003","article-title":"Respiratory Effectiveness Group (REG). Changes in control status of COPD over time and their consequences: a prospective international study","volume":"57","author":"Miravitlles","year":"2021","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2023.07.015_bib0290","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.chest.2019.11.004","article-title":"Evaluation of changes in control status in COPD: an opportunity for early intervention","volume":"157","author":"Soler-Catalu\u00f1a","year":"2020","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2023.07.015_bib0295","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2147\/COPD.S160842","article-title":"Determinants of medical prescriptions for COPD care: an analysis of the EPOCONSUL clinical audit","volume":"13","author":"L\u00f3pez-Campos","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2023.07.015_bib0300","doi-asserted-by":"crossref","first-page":"e0141856","DOI":"10.1371\/journal.pone.0141856","article-title":"Clinical audits in outpatient clinics for chronic obstructive pulmonary disease: methodological considerations and workflow","volume":"10","author":"Lopez-Campos","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.arbres.2023.07.015_bib0305","first-page":"1053","article-title":"The reasons for triple therapy in stable COPD patients in Japanese clinical practice","volume":"10","author":"Miyazaki","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2023.07.015_bib0310","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1183\/09031936.00162313","article-title":"Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011?","volume":"43","author":"Burgel","year":"2014","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2023.07.015_bib0315","first-page":"2207","article-title":"The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK","volume":"10","author":"Brusselle","year":"2015","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2023.07.015_bib0320","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4104\/pcrj.2013.00073","article-title":"Everyday clinical practice and its relationship to 2010 and 2011 GOLD guideline recommendations for the management of COPD","volume":"22","author":"Papala","year":"2013","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.arbres.2023.07.015_bib0325","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4104\/pcrj.2013.00016","article-title":"A new approach to grading and treating COPD based on clinical phenotypes: summary of the Spanish COPD guidelines (GesEPOC)","volume":"22","author":"Miravitlles","year":"2013","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.arbres.2023.07.015_bib0330","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3399\/bjgp12X625111","article-title":"Difficulties in differential diagnosis of COPD and asthma in primary care","volume":"62","author":"Miravitlles","year":"2012","journal-title":"Br J Gen Pract"},{"key":"10.1016\/j.arbres.2023.07.015_bib0335","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.arbres.2020.07.032","article-title":"Treatment pathways before and after triple therapy in COPD: a population-based study in primary care in Spain","volume":"57","author":"Monteagudo","year":"2021","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2023.07.015_bib0340","doi-asserted-by":"crossref","first-page":"1801586","DOI":"10.1183\/13993003.01586-2018","article-title":"Triple therapy versus single and dual longacting bronchodilator therapy in COPD: a systematic review and meta-analysis","volume":"52","author":"Cazzola","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2023.07.015_bib0345","doi-asserted-by":"crossref","first-page":"2000351","DOI":"10.1183\/13993003.00351-2020","article-title":"Withdrawal of inhaled corticosteroids in chronic obstructive pulmonary disease: a European respiratory society guideline","volume":"35","author":"Chalmers","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2023.07.015_bib0350","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.02.00269802","article-title":"A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease","volume":"19","author":"Casaburi","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1016\/j.arbres.2023.07.015_bib0355","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1378\/chest.122.1.47","article-title":"A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol","volume":"122","author":"Donohue","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.arbres.2023.07.015_bib0360","doi-asserted-by":"crossref","first-page":"823","DOI":"10.2147\/COPD.S154791","article-title":"Depressive status explains a significant amount of the variance in COPD assessment test (CAT) scores","volume":"13","author":"Miravitlles","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.arbres.2023.07.015_bib0365","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.arbres.2019.11.011","article-title":"The clinical implications of triple therapy in fixed-dose combination in COPD: from the trial to the patient","volume":"56","author":"L\u00f3pez-Campos","year":"2020","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2023.07.015_bib0370","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1136\/thoraxjnl-2015-207021","article-title":"Blood eosinophils and inhaled corticosteroid\/long-acting \u03b2-2 agonist efficacy in COPD","volume":"71","author":"Pavord","year":"2016","journal-title":"Thorax"},{"key":"10.1016\/j.arbres.2023.07.015_bib0375","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.arbres.2019.09.015","article-title":"Plasma eosinophil count and patient-centered events in chronic obstructive pulmonary disease in real-life clinical practice","volume":"56","author":"Golpe","year":"2020","journal-title":"Arch Bronconeumol"},{"key":"10.1016\/j.arbres.2023.07.015_bib0380","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1378\/chest.15-1055","article-title":"Defining the asthma-COPD overlap syndrome in a COPD cohort","volume":"149","author":"Cosio","year":"2016","journal-title":"Chest"}],"container-title":["Archivos de Bronconeumolog\u00eda"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289623002302?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0300289623002302?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:43:12Z","timestamp":1759531392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0300289623002302"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0300289623002302"],"URL":"https:\/\/doi.org\/10.1016\/j.arbres.2023.07.015","relation":{},"ISSN":["0300-2896"],"issn-type":[{"value":"0300-2896","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhaled Maintenance Therapy in the Follow-Up of COPD in Outpatient Respiratory Clinics. Factors Related to Inhaled Corticosteroid Use. EPOCONSUL 2021 Audit","name":"articletitle","label":"Article Title"},{"value":"Archivos de Bronconeumolog\u00eda","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arbres.2023.07.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 SEPAR. Published by Elsevier Espa\u00f1a, S.L.U. All rights reserved.","name":"copyright","label":"Copyright"}]}}